

HR 4629

Star Rating for Biosimilars Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 8, 2019

Current Status: Sponsor introductory remarks on measure. (CR H8232)

Latest Action: Sponsor introductory remarks on measure. (CR H8232) (Oct 18, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4629>

Sponsor

Name: Rep. Tonko, Paul [D-NY-20]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gibbs, Bob [R-OH-7]	R · OH		Oct 8, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 9, 2019
Ways and Means Committee	House	Referred to	Oct 8, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 3	Related bill	Sep 8, 2020: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
116 S 4199	Related bill	Jul 2, 2020: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
116 S 2543	Related bill	Sep 25, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.

Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

Actions Timeline

- **Oct 18, 2019:** Sponsor introductory remarks on measure. (CR H8232)
- **Oct 9, 2019:** Referred to the Subcommittee on Health.
- **Oct 8, 2019:** Introduced in House
- **Oct 8, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 8, 2019:** Referred to the Subcommittee on Health.